Please assess the completion status of the following clinical trial:

Trial Title: Probiotics as Adjuvant Treatment for Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 to 65 years old, with history of sexual activity, premenopausal women；~2. Nugent Score ≥ 7 for diagnosing BV；~3. Sign informed consent.~Exclusion Criteria:~1. mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection or gonococcal vaginitis;~2. History of systemic organic diseases or psychiatric diseases;~3. Planning for or during pregnancy, lactation, menstruation;~4. within 5 days of onset of the disease, any antibiotics has been used;~5. Long-term use of contraceptives or immunosuppressant;~6. Anaphylactic constitution or allergic to known ingredients of research drugs.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Probiotics and Metronidazole (Type: EXPERIMENTAL): Probiotics: Oral probiotics(Umeta-Miyue, Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14) ) (qd, 30 days); Metronidazole: Metronidazole vaginal suppositories (qd,7 days)
- Metronidazole vaginal (Type: ACTIVE_COMPARATOR): Metronidazole vaginal suppositories(1 suppositories,qd,7 days )

Based on this trial design, predict the completion outcome and termination type (if applicable).